Merck rolls out 3 new Keytruda prostate cancer studies by Carly Helfand Thursday, February 14, 2019 If Merck gets its way, it won’t be long before the prostate cancer treatment landscape looks pretty different.
Big Keytruda win sets Merck up to steal BMS' kidney cancer share by Carly Helfand Tuesday, February 12, 2019 BMS investors have been dreading positive kidney cancer results from Merck for months. And those results might even be better than they expected.
Merck's Keytruda nabs priority head and neck cancer review by Carly Helfand Monday, February 11, 2019 Merck’s Keytruda is duking it out with BMS' Opdivo in head and neck cancer, but Keytruda just took one step toward a big edge.
Merck analysts to CEO Frazier: What’s so great about the pipeline? by Arlene Weintraub Friday, February 1, 2019 Merck's 2019 sales expectations are on the low side of what analysts expected, intensifying concerns about growth beyond I-O star Keytruda.
BMS, Roche will top burgeoning I-O market worth $29B: analyst by Angus Liu Monday, January 28, 2019 The adjuvant use of I-O therapies could be a $29 billion market, currently led by BMS and Roche, according to Credit Suisse analysts.
Look out for an Opdivo surprise in Q4: analyst by Carly Helfand Wednesday, January 23, 2019 For the fourth quarter, analysts expect Keytruda to maintain its lead over Opdivo. But it’s Opdivo that could surprise Wall Street, one analyst says.
Merck adds real doctor to latest ‘Tru’ patient TV ads by Beth Snyder Bulik Wednesday, January 16, 2019 Merck's latest additions to the multichannel "It's Tru" campaign for cancer drug Keytruda include two TV ads featuring a real oncologist.
Exelixis takes Cabometyx into crowded liver cancer field by Angus Liu Tuesday, January 15, 2019 Exelixis nabbed an FDA nod for Cabometyx in second-line liver cancer, where Stivarga, Opdivo and Keytruda are already battling it out.
Merck's Keytruda slashes death risk by 31% in esophageal cancer by Carly Helfand Monday, January 14, 2019 In November, Merck said Keytruda had topped chemo at lengthening the lives of esophageal cancer patients. Monday, it showed the win was a big one.
Pfizer, Merck topped the Dow in 2018 despite biopharma declines by Arlene Weintraub Wednesday, January 2, 2019 Key oncology wins helped drive Pfizer and Merck to the top of the Dow in 2018, but the pharma sector faces plenty of hurdles this year.